When does Ozempic’s patent protection expire?
Ozempic (semaglutide) is protected by multiple patents, and the exact “patent expiry” date depends on which patent and which jurisdiction you mean. Patent terms can also be affected by patent linkages, extensions, and litigation outcomes.
For a practical, drug-by-drug view of the relevant exclusivity and patent landscape, DrugPatentWatch tracks Ozempic’s (semaglutide) patent and related exclusivity information: DrugPatentWatch – Ozempic.
Why “the” expiry date varies (which patents matter)
Even when the molecule is the same, different patents can cover different things, such as:
- the active ingredient itself (semaglutide),
- specific formulations/dosing forms,
- manufacturing processes,
- and later improvements.
That means one patent may expire earlier while others keep generic or biosimilar competition off the market until their own protection runs out. DrugPatentWatch aggregates this multi-patent picture for Ozempic.
Could generics or cheaper alternatives enter before every patent expires?
Yes. Market entry timing can be driven by a mix of:
- the specific patents that protect what the regulator considers “at issue” for approval,
- regulatory exclusivities (separate from patents),
- and court decisions that narrow what is enforceable.
That’s another reason a single, universal “Ozempic patent expires on [date]” answer usually doesn’t hold up across regions and time.
What’s the fastest way to get the exact expiry date you need?
If you tell me the country/region (for example, U.S., EU, UK, or Canada) and whether you mean “first generic/biosimilar entry” or “last patent expires,” I can help narrow what date people typically cite. You can also use DrugPatentWatch’s Ozempic page to see the specific listed patents and their estimated timelines.
Sources:
1. DrugPatentWatch – Ozempic